<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341832</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-1203_P2</org_study_id>
    <nct_id>NCT03341832</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of NVP-1203 in Patients With Acute Low Back Pain</brief_title>
  <official_title>A Randomized, Double-blind, Active- and Placebo-controlled, Parallel, Multicenter, Phase II an Exploratory Clinical Trial to Evaluate the Efficacy and Safety NVP-1203 in Patients With Acute Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety NVP-1203 in patients with
      Acute low back pain
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, active- and placebo-controlled, parallel, phase II
      study to evaluate efficacy and safety of NVP-1203 in patients with Acute low back pain
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Actual">January 15, 2019</completion_date>
  <primary_completion_date type="Actual">January 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS Pain Intensity</measure>
    <time_frame>3, 7 days</time_frame>
    <description>Improvement in VAS compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Finger to Floor Distance (FFD)</measure>
    <time_frame>3, 7 days</time_frame>
    <description>Improvement in FFD compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index(ODI)</measure>
    <time_frame>3, 7 days</time_frame>
    <description>Improvement in ODI compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment of Response to Therapy(IGART)</measure>
    <time_frame>7 days</time_frame>
    <description>Improvement in IGART compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Acute Low Back Pain</condition>
  <arm_group>
    <arm_group_label>NVP-1203</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1203-R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203</intervention_name>
    <description>oral dose for 7 days</description>
    <arm_group_label>NVP-1203</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203-R</intervention_name>
    <description>oral dose for 7 days</description>
    <arm_group_label>NVP-1203-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203 placebo</intervention_name>
    <description>oral dose for 7 days</description>
    <arm_group_label>NVP-1203-R</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203-R placebo</intervention_name>
    <description>oral dose for 7 days</description>
    <arm_group_label>NVP-1203</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have ability to comprehend the contents of study and before participating
             in trial and have willingness to sign of informed consent in writing

          -  19 Years and older

          -  A patient has symptom of acute low back pain

        Exclusion Criteria:

          -  Subjects who cannot prohibit anti-inflammatory drug or muscle relaxants during
             clinical trial

          -  Inadequate subject for the clinical trial by the investigator's decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong-Hwan Moon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Hwan Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Kyun Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonkwang University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Navipharm</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16209</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

